HeartFlow Achieves Landmark Milestone of 250,000 Patients Assessed for Coronary Artery Disease (CAD) with FFRCT Analysis

This patient milestone and the recent launch of Plaque Analysis and RoadMapTM Analysis further solidify HeartFlow as a pioneer in AI-enabled CAD diagnostics

MOUNTAIN VIEW, Calif. – January 3, 2024 — HeartFlow, Inc., a leader in non-invasive artificial intelligence (AI) precision coronary care solutions, today announced that it has surpassed 250,000 patients receiving a HeartFlow FFRCT Analysis. This accomplishment is a testament to HeartFlow’s dedication to driving a new standard of care and marks an important milestone for the company.

Traditional methods of non-invasive ischemia testing (stress EKG, stress echo, SPECT, PET, direct-to-cath) can result in false negatives 20-30 percent of the time, which can lead to undetected disease, and false positives over 50 percent of the time, which can lead to unnecessary invasive procedures.1,2  Together, Coronary Computed Tomography Angiography (CCTA) and HeartFlow’s FFRCT are part of a new standard of care that non-invasively diagnoses CAD and provides guidance on subsequent treatment decisions. HeartFlow’s FFRCT provides clear insights into each patient’s condition with a patient-specific visual model of the heart’s blood flow.  With more than 500 peer-reviewed publications, the HeartFlow FFRCT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes.3 HeartFlow’s FFRCT Analysis is covered by Medicare and for >99% of commercially insured lives.

Since its inception, HeartFlow has been committed to building a new standard of care for people at risk of heart disease. For over a decade, HeartFlow’s deep partnerships with more than 1,000 hospitals globally, including 80% of the top 50 heart hospitals in the U.S., have advanced coronary care while also allowing customers to grow and scale their CCTA programs. HeartFlow is committed to serving customers quickly and reliably with a median turnaround time less than 1.5 hours.4 In addition, HeartFlow accepts ~95% of all CCTAs submitted by customers for an FFRCT analysis.5 

To further underscore HeartFlow’s commitment to innovation, 2023 marked the release of its Plaque Analysis – the only FDA cleared plaque analysis with a reported 95% agreement compared to the gold standard, IVUS, in quantification and characterization of total plaque volume as shown in the REVEALPLAQUE study presented at the 2023 SCCT annual conference.6 Also in 2023, HeartFlow released its RoadMapTM Analysis which helps identify and quantify narrowings in the coronary arteries and has demonstrated a 25% faster CCTA read time.7

While HeartFlow was founded with FFRCT technology, the company has evolved from a single product used to assess the impact that narrowing vessels have on coronary blood flow (FFRCT Analysis), to a comprehensive suite of non-invasive technologies that build on CCTA. This FDA-cleared, comprehensive portfolio of technologies positions HeartFlow as the leader in the field of cardiac care – the first and most comprehensive AI-based decision tool empowering physicians in diagnosing and treating heart disease with unparalleled depth and precision.

“Accurate and timely diagnosis and treatment are fundamental to providing effective care, minimizing risks, preventing complications and improving the overall health for patients with CAD,” said Daniel I. Simon, M.D., President, Academic & External Affairs and Chief Scientific Officer, University Hospitals Health System. “Our long-standing partnership with HeartFlow has directly contributed to enhanced diagnostic precision, improved turnaround times, a reduction in false positives and negatives, and a better patient experience. Complementing our clinical expertise, HeartFlow’s portfolio allows us to navigate the complex cardiac diagnostic and treatment process with enhanced visibility, greater confidence and the assurance that we are maximizing the potential for improved outcomes.”

“We are extremely proud of achieving the 250,000 patient milestone with our physician partners. Our collective team shares in our excitement for the future and are eager to build on this success.”  said John Farquhar, Chief Executive Officer at HeartFlow. “We’ve experienced a year of notable accomplishments and growth including the expansion of our product portfolio with Plaque Analysis and RoadMapTM Analysis. Our continued commitment to developing a new standard of care for patients at risk of heart disease remains steadfast and we look forward to surpassing more milestones in the future.” 


About HeartFlow

HeartFlow is transforming precision coronary care with the only AI-powered non-invasive integrated heart care solution across the CCTA pathway. As the pioneer of FFRCT, which is now supported by the ACC/AHA Chest Pain Guidelines, HeartFlow continues to advance the diagnosis and management of CAD. For more information, visit www.heartflow.com and connect on Twitter and LinkedIn.



Linly Ku

  1. Arbab-Zadeh, Heart Int 2012. Yokota, et al. Neth Heart J 2018. Nakanishi, et al. J Nucl Cardiol 2016.
  2. Patel et al. NEJM 2010.
  3. 2021 ACC/AHA Chest Pain Guidelines.
  4. Turnaround time is defined as the time it takes from customer CCTA submission for HeartFlow to deliver back the FFRCT Analysis. US median turnaround time. Data on file.
  5. Data on file.
  6.  REVEALPLAQUE Study, SCCT 2023.
  7. Morris, et al. A Study to Measure the Ability of AI-CSQ to support the busy CCTA reader: SMART-CT. JCCT 2023.

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!


HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。


さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.